The estimated Net Worth of Caryn Gordon Mc Dowell is at least $1.19 millió dollars as of 6 June 2022. Ms Dowell owns over 10,800 units of Cortexyme Inc stock worth over $238,875 and over the last 8 years she sold CRTX stock worth over $433,196. In addition, she makes $513,164 as Chief Legal & Admin. Officer and Corp. Sec. at Cortexyme Inc.
Ms has made over 7 trades of the Cortexyme Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently she sold 10,800 units of CRTX stock worth $30,888 on 6 June 2022.
The largest trade she's ever made was selling 13,181 units of Cortexyme Inc stock on 6 October 2017 worth over $204,174. On average, Ms trades about 2,631 units every 88 days since 2017. As of 6 June 2022 she still owns at least 122,500 units of Cortexyme Inc stock.
You can see the complete history of Ms Dowell stock trades at the bottom of the page.
Caryn Gordon McDowell is the Chief Legal & Admin. Officer and Corp. Sec. at Cortexyme Inc.
As the Chief Legal & Admin. Officer and Corp. Sec. of Cortexyme Inc, the total compensation of Ms McDowell at Cortexyme Inc is $513,164. There are 8 executives at Cortexyme Inc getting paid more, with Michael Detke having the highest compensation of $1,100,170.
Ms McDowell is 51, she's been the Chief Legal & Admin. Officer and Corp. Sec. of Cortexyme Inc since . There are 13 older and 4 younger executives at Cortexyme Inc. The oldest executive at Cortexyme Inc is Una Ryan, 78, who is the Lead Independent Director.
Caryn's mailing address filed with the SEC is C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO, CA, 94080.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi és Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: